Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (6) clinical trials

High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs

Lymphedema is a condition afflicting cancer patients who undergo surgery with removal of lymph nodes, chemotherapy and radiation. Lymphedema is a consequence of impaired lymphatic drainage in the interstitium, which causes edema and inflammation in the subcutaneous tissue. The symptoms are swelling, puffiness, tightness, heaviness and pain in the affected ...

Phase N/A

Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a dose level of NK cells based on when you join this study. Up to 2 dose levels of NK cells will be tested. Up to 6 participants will be ...


Denosumab + Pembrolizumab in Patients With Stage IV Melanoma

STUDY OBJECTIVES Co-primary Objectives Assess the mechanistic (immune-mediated and/or direct antitumor effect) and pharmacodynamics effect (tissue saturation studies) of denosumab alone (i.e., after two loading doses of denosumab are given on day 1 and day 8) in patients with unresectable stage III or distant metastatic PD-1/PD-L1 inhibitor-nave cutaneous melanoma (stage ...


Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design for up to 17 cycles. Participants who receive placebo or who stop ...


A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.


Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions

Background Malignant melanoma (MM) is a deadly cancer, claiming globally about 160000 new cases per year and 48000 deaths [1]. The incidence rate for MM ascended between 1950 and 2007 more than 17-fold in men (1.9 to 33.5 per 100,000) and more than 9-fold in women (2.6 to 25.3 per ...

Phase N/A